Trevi Therapeutics, Inc. (TRVI)
- Previous Close
2.5400 - Open
2.5000 - Bid 2.7200 x 100
- Ask 2.8100 x 100
- Day's Range
2.5000 - 2.8000 - 52 Week Range
0.9700 - 4.0000 - Volume
53,740 - Avg. Volume
298,058 - Market Cap (intraday)
191.709M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2900 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.33
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
www.trevitherapeutics.comRecent News: TRVI
Performance Overview: TRVI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRVI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRVI
Valuation Measures
Market Cap
191.71M
Enterprise Value
110.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.32
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.85
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.96%
Return on Equity (ttm)
-30.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.07M
Diluted EPS (ttm)
-0.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
82.97M
Total Debt/Equity (mrq)
1.62%
Levered Free Cash Flow (ttm)
-21.97M